Articles tagged with: Genvoya

Multiple provinces and territories demonstrate leadership in the treatment of HIV/AIDS by providing access to GENVOYA®

published: May, 17, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Current Affairs, General Health, Treatment Guidelines -including when to start, Health, Revolving Door, Treatment, Guest Authors

Gilead's first TAF-based single tablet regimen demonstrates high efficacy with improved renal and bone parameters compared to TDF-based regimens.

Multiple provinces and territories demonstrate leadership in the treatment of HIV/AIDS by providing access to GENVOYA®

MISSISSAUGA, ON, May 4, 2017 /CNW/ - Gilead Sciences Canada, Inc. today announced that GENVOYA® tablets, for the treatment of HIV-1 infection, is now listed in multiple provinces and territories including, Ontario, Alberta, Quebec and Yukon, as well as in the Non-Insured Health Benefits (NIHB) Drug Plan for First Nations and Inuit. GENVOYA (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide) is indicated as a complete regimen for the treatment of h

Gilead receives approval in Canada for ODEFSEY™ for the treatment of HIV1 infection.

published: March, 07, 2017 Written by // Guest Authors - Revolving Door

Odefsey is the second single tablet regimen containing the Descovy™ backbone and the third product in Gilead’s new TAF portfolio to receive approval in Canada.

Gilead receives approval in Canada for ODEFSEY™ for the treatment of HIV1 infection.

Mississauga, On, February 16, 2017 – Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for ODEFSEY™ (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg) tablets as a complete regimen for the treatment of adults with HIV-1 infection. ODEFSEY is the most recent product approved from Gilead Canada’s range of tenofovir alafenamide (TAF)-based regimens that include GENVOYA® and DESCOVY™. ODEFSEY is indi

Lots to be thankful for and lots to challenge us as 2017 opens.

published: January, 25, 2017 Written by // Louis "Kengi" Carr - L.A. Correspondent Categories // African, Caribbean and Black, Social Media, Community Events, Gay Men, Current Affairs, Photography, Pets, Health, International , Treatment, Living with HIV, Opinion Pieces, Louis "Kengi" Carr

Our L.A. guy Kengi says 2017 is sure to be a challenging year.

Lots to be thankful for and lots to challenge us as 2017 opens.

As I sit down to write this entry I do so with a heavy heart, but a spirit that is encouraged. I say this because my Great Aunt is still not doing well and last night I received word that one of her daughters, my cousin, has suffered a stroke. They both are recovering in separate hospitals. Your good thoughts, affirmations and prayers are greatly appreciated. I’m encouraged and even comforted because I know God, my creator, will provide what is best for them both. So, I guess I should say H

My year end reflection: Just leave, 2016, enough!

published: December, 21, 2016 Written by // Wayne Bristow - Positive Life Categories // Aging, Social Media, Gay Men, Health, Treatment, Living with HIV, Opinion Pieces, Wayne Bristow

Wayne Bristow reflects on a difficult medication change, on how hard it can be to forgive people and the necessity and virtue of self care.

My year end reflection: Just leave, 2016, enough!

I see many people on social media talking about 2016 being the worst of years for them. There were times I praised it because there were many good things that happened for me. But the last month or so I’ve been confronted with some not so good things that have surfaced to the top of the attention pile. My pros and cons list has equaled itself out. In my last posting I spoke of my upcoming doctor’s appointment and how I wasn’t going to overthink things or see things that weren’t really

Gilead’s new price hikes on HIV drugs anger AIDS activists

published: July, 15, 2016 Written by // Guest Authors - Revolving Door Categories // African, Caribbean and Black, Gay Men, Youth, Current Affairs, Newly Diagnosed, Women, Health, Revolving Door, Guest Authors

Gilead hikes price of HIV therapies, other drugs by up to 10 percent

Gilead’s new price hikes on HIV drugs anger AIDS activists

This article by Ed Silverman @Pharmalot previously appeared on the Stat website, where you can read the whole story. As part of a strategy to switch patients to newer HIV treatments, Gilead Sciences late last week raised prices on a pair of older HIV medications that face patent expiration. This sort of maneuver is often found in the pharmaceutical playbook, but is triggering still more criticism by AIDS activists of its overall pricing strategies. Here’s what Gilead did: the company